Navigation Links
Alfacell Reports Financial Results for First Quarter of Fiscal 2008
Date:12/10/2007

SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the first quarter of fiscal 2008.

The company recorded a net loss of approximately $2.7 million, or $0.06 per basic and diluted common share, for the fiscal quarter ended Oct. 31, compared to a net loss of $2.4 million, or $0.05 per basic and diluted common share, for the first quarter of fiscal 2007. General and administrative expenses increased by approximately $0.2 million, and investment income decreased by approximately $0.1 million, during the first quarter of fiscal 2008 as compared to the same quarter a year ago.

Cash and Liquidity

As of Oct. 31, the company had cash and cash equivalents of approximately $5.4 million, a decrease of approximately $1.6 million from cash and cash equivalents of approximately $7.0 million at July 31. The company believes that this level of cash and cash equivalents is sufficient to support its activities through the first quarter of fiscal 2009 based on the current expected level of receipts and expenditures.

"Fiscal 2008 is off to a promising start," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "Upon reaching the necessary number of evaluable events in our confirmatory Phase IIIb clinical trial for ONCONASE(R), we will begin the required statistical analysis. Our rolling NDA submission for ONCONASE continues as planned and is our primary focus in fiscal 2008."

Clinical Trials Update

Alfacell has completed patient enrollment in the confirmatory Phase IIIb clinical trial for ONCONASE (ranpirnase) in patients suffering from unresectable malignant mesothelioma. A total of 428 patients were enr
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... Ky. , Sept. 30, 2014 A ... tomography (OCT), offered a new look at the composition ... alter how physicians understand and treat the disease, a ... conducted at Baptist Health Lexington between September 2010 and ... of the Journal of the American College of ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Despite difficult economic conditions, Allied Healthcare Products (Nasdaq: ... in the first quarter of fiscal year 2011. Sales increased ... for the first quarter of fiscal 2010. An ... carbon dioxide absorbent products used in anesthesia procedures narrowly tipped ...
... Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... a $2 million medical device distribution bid for a ... Bank Corp ("CDB"). CDB is a ...
Cached Medicine Technology:Allied Healthcare Products Reports Narrow Loss for Quarter But Improves Year-Over-Year Performance 2Allied Healthcare Products Reports Narrow Loss for Quarter But Improves Year-Over-Year Performance 3Allied Healthcare Products Reports Narrow Loss for Quarter But Improves Year-Over-Year Performance 4Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project 2Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project 3
(Date:10/1/2014)... Nordic Naturals is kicking off a ... The campaign—“Buy One Bottle. Help Two Heroes.”—will raise ... nonprofit organization that helps rebuild the lives of ... would otherwise face euthanasia. From October through December ... donations of Nordic Naturals omega-3s to veterans and ...
(Date:10/1/2014)... 01, 2014 Two bicyclists began a ... across the country in an effort to raise funds ... The cyclists, a father-daughter team, plan to bike ... Blaine, Washington and finishing in Key West Florida. ... The Warriors®, a national nonprofit organization that assists post-9/11 ...
(Date:10/1/2014)... TORONTO, Oct. 1, 2014 Long-acting insulin is ... patients with Type 1 diabetes, according to new ... , Researchers looked at once-daily and twice-daily doses ... effectiveness, safety and cost-effectiveness. , "In patients ... insulin is superior to intermediate-acting insulin when it ...
(Date:10/1/2014)... 2014 Indosoft, Inc., a leading provider of ... it has added support for Sangoma Lyra ... Indosoft have a history of bringing innovative products to ... offers a significant benefit to those using Asterisk as a ... available to users of Q-Suite. , In the past decades, ...
(Date:10/1/2014)... Nearly a year-and-a-half after filing his lawsuit, ... jury awarded him $4.75 million; Michael D. Casper passed ... Casper had been too sick to be present during ... Court Documents (District Court, Pueblo County 12CV740,  Division D), ... condition of his prostate, when he purchased a first ...
Breaking Medicine News(10 mins):Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3
... 19 GlaxoSmithKline (NYSE: GSK ),today reported ... million, equivalent to almost 4% of pre-tax profits ... 1%). Donations of albendazole treatments,for the company,s flagship ... were valued at $29 million, bringing the,total number ...
... in heparin samples , , WEDNESDAY, March 19 (HealthDay News) ... found in the blood-thinner heparin, which has been linked ... in the United States. , The contaminant is a ... and Drug Administration officials could not say Wednesday how ...
... before ... Patients, ST. LOUIS ... side, International Union of Operating,Engineers Local 49 leaders today at a news ... medical coverage to,several thousand Minnesota seniors., "This is a death sentence ...
... drug-resistant bacteria, CDC study finds , , WEDNESDAY, March 19 ... aureas bacterium and caught outside of the hospital ... than previously believed, preliminary research suggests. , "Over the ... a severe CAP [community-acquired pneumonia] caused by S. ...
... at the University of Pennsylvania School of Medicine have ... the molecular pathways underlying sleep apnea, which affects more ... of Health. Sleep apnea is a condition characterized by ... occur dozens or even hundreds of times a night. ...
... (PRI),and Medicos, Inc. are pleased to announce that over ... mobile version of,the MPR drug databases. For over 23 ... print editions of MPR for up-to-date, concise drug,information at ... drug,information on computers and mobile devices in all 50 ...
Cached Medicine News:Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:Park Nicollet to Cut Off Care to Thousands of Minnesota Seniors 2Health News:Community-Based Staph Pneumonia More Common Than Thought 2Health News:Molecular biology of sleep apnea could lead to new treatments 2Health News:eMPR Digital Drug Reference Reaches 50,000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 2Health News:eMPR Digital Drug Reference Reaches 50,000 Downloads and the Publisher Launches a Raffle for Healthcare Providers 3
... IntraLase FS laser introduces new high precision ... now have the opportunity to offer their ... a microkeratome for creating the corneal flap. ... laser and proprietary IntraLASIK software, surgeons may ...
... Teco Diagnostics manufactures fine urine chemistry ... urine chemistry reagent strips from start ... offer more economical prices compared to ... quality. Teco Diagnostics urine reagent strips ...
... with diabetes continue to have a tremendous ... life of patients, in addition to the ... to be associated with elevated levels of ... of haemoglobin A1c (HbA1c) in a diabetic ...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program....
Medicine Products: